A new direction for anticoagulants: Inhibiting fibrin assembly with PEGylated fibrin knob mimics

Biotechnology and Bioengineering

Volumn 108, Issue 10, 2011, Pages 2424-2433

  Stabenfeldt, Sarah E ^a   Aboujamous, Nader M ^a   Soon, Allyson S C ^a   Barker, Thomas H ^a  

^a Emory University   (United States)

Author keywords

Coagulation; Fibrinogen; Polyethylene glycol

Indexed keywords

ACTIVE PEPTIDES; ANTICOAGULANT ACTIVITIES; ANTICOAGULANT PROPERTIES; BIPHASIC EFFECTS; CLOT FORMATION; COAGULATION FACTOR; CONTROL LEVEL; FIBRIN CLOTS; FIBRINOGEN; HUMAN PLASMAS; MOLAR RATIO; NEW DIRECTIONS; PEPTIDE SEQUENCES; PHARMACOKINETICS AND PHARMACODYNAMICS; PROTHROMBIN TIME; THERAPEUTIC RANGE;

CHAIN LENGTH; COAGULATION; GLYCOLS; PATIENT MONITORING; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENES; POLYMERIZATION; POLYMERS; THERMOPLASTICS;

KNOBS;

ANTICOAGULANT AGENT; CYSTEINE DERIVATIVE; FIBRIN; FIBRINOGEN; MACROGOL; PEGYLATED FIBRIN KNOB A PEPTIDE; PEPTIDE; PEPTIDE DERIVATIVE; THROMBIN; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; MACROGOL DERIVATIVE;

AMINO ACID SEQUENCE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONJUGATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; FIBRIN POLYMERIZATION; HUMAN; PLASMA; PROTEIN PURIFICATION; PROTHROMBIN TIME; CHEMISTRY; PROCEDURES;

ANTICOAGULANTS; BIOMIMETIC MATERIALS; BLOOD COAGULATION; FIBRIN; HUMANS; PEPTIDES; PLASMA; POLYETHYLENE GLYCOLS; PROTHROMBIN TIME;

EID: 80051802611     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23184     Document Type: Article

References (22)

1. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. 2001. Rational design of a potent, long-lasting form of interferon: A 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12(2): 195-202.
2. Blomback B. 1958. Studies on fibrinogen: Its purification and conversion into fibrin. Acta Physiol Scand Suppl 43(148): 1-51.
3. Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF. 1999. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 27(3): 425-432.
4. Carr ME, Kaminski M, Mcdonagh J, Gabriel DA. 1985. Influence of ionic-strength, peptide release and calcium on the structure of reptilase and thrombin derived fibrin gels. Thromb Haemost 54(1): 159-159.
5. Carr ME, Gabriel DA, Mcdonagh J. 1987. Influence of factor-Xiii and fibronectin on fiber size and density in thrombin-induced fibrin gels. J Lab Clin Med 110(6): 747-752.
6. Davie EW, Fujikawa K, Kisiel W. 1991. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30(43): 10363-10370.
7. Doolittle RF. 1984. Fibrinogen and fibrin. Annu Rev Biochem 53:195-229.
8. Dvorak M, Vlasin M, Dvorakova M, Rauser P, Lexmaulova L, Gregor Z, Staffa R. 2010. Heparin and its derivatives in the treatment of arterial thrombosis: A review. Vet Med 55(11): 523-546.
9. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. 2003. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 55(10): 1279-1291.
10. Everse SJ, Pelletier H, Doolittle RF. 1995. Crystallization of fragment-D from human fibrinogen. Protein Sci 4(5): 1013-1016.
11. Gogstad GO, Dahl KH, Christophersen A, Bjerke A. 1986. Turbidimetric determination of prothrombin time by clotting in a centrifugal analyzer. Clin Chem 32(10): 1857-1862.
12. Gong XW, Wei DZ, He ML, Xiong YC. 2007. Discarded free PEG-based assay for obtaining the modification extent of pegylated proteins. Talanta 71(1): 381-384.
13. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. 2011. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res 127(1): 29-34.
14. Laudano AP, Doolittle RF. 1978. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 75(7): 3085-3089.
15. Laudano AP, Doolittle RF. 1980. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 19(5): 1013-1019.
16. Lord ST. 2007. Fibrinogen and fibrin: Scaffold proteins in hemostasis. Curr Opin Hematol 14(3): 236-241.
17. Meddahi S, Samama MM. 2009. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Blood Coagul Fibrinolysis 20(3): 207-214.
18. Orfeo T, Butenas S, Brummel-Ziedins KE, Gissel M, Mann KG. 2010. Anticoagulation by factor Xa inhibitors. J Thromb Haemost 8(8): 1745-1753.
19. Pasut G, Veronese FM. 2007. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 32(8-9): 933-961.
20. Reddy KR, Modi MW, Pedder S. 2002. Use of peginterferon alfa-2a (40kD) (Pegasys (R)) for the treatment of hepatitis C. Adv Drug Deliv Rev 54(4): 571-586.
21. Stabenfeldt SE, Gossett JJ, Barker TH. 2010. Building better fibrin knob mimics: An investigation of synthetic fibrin knob peptide structures in solution and their dynamic binding with fibrinogen/fibrin holes. Blood 116(8): 1352-1359.
22. Zhang G, Han B, Lin X, Wu X, Yan H. 2008. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J Biochem 144(6): 781-788.